Editing out HIV from infected T-Cells using CRISPR/Cas9

Kaminski et al, Scientific Reports, (2016) 6:22555 http://www.ncbi.nlm.nih.gov/pubmed/26939770

While treatments for HIV have vastly improved in the last decades, HIV positive patients require a lifelong regiment of anti-viral drugs due to HIV genomes integrating into CD4+ T-cells.  Researchers from Temple University and Case Western Reserve University have reported using CRISPR/Cas9 gene editing technology to remove the entire HIV genome from infected T-cells ex vivo.  Importantly, no significant off-target effects were found, providing evidence that this technique may be clinically viable in the future.

Author: Advanced Analytical

Advanced Analytical Technologies, Inc. (AATI) simplifies complex genomics workflows to accelerate research and discovery in pharmaceuticals, life science, biofuels, biotechnology and healthcare.

Leave a Reply